feedback

Course Director

Nathan H. Fowler, MD
Nathan H. Fowler, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty

Matthew S. Davids
Matthew S. Davids, MD, MMSc

Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Sonali M. Smith
Sonali M. Smith, MD

The University of Chicago Medicine
Chicago, Illinois

Accredited by

Penn State College of Medicine

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2018-Oct-09
Expiration Date:2019-Oct-08
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

In this activity, experts in non-Hodgkin lymphoma discuss the best way to utilize novel therapeutics in chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), or mantle cell lymphoma (MCL) while also considering prognostic factors, issues such as treatment history, and molecular features or cytogenetics. The faculty also addresses the unique safety profiles of agents such as BTK, PI3K, and Bcl-2 inhibitors, novel antibodies, and immunomodulating agents, while also describing potential future applications such as novel combination approaches in a range of B-cell cancers. This MasterClass and Tumor Board learning session features several clinical and patient scenarios that open each scientific discussion and help to illustrate how novel therapeutics are making a difference in the care of patients with CLL, FL, or MCL.

Upon completion of this activity, participants should be better able to:
  • Summarize evidence on the safety and efficacy of BCR inhibitors, next-generation antibodies, immunomodulators, and other emerging strategies in the management of B-cell malignancies
  • Recommend therapy with novel agents for newly diagnosed or relapsed/refractory B-cell cancers such as FL, CLL, and MCL
  • Manage adverse events in patients with B-cell malignancies receiving therapy with regimens that contain novel agents

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, and other healthcare professionals involved in the care of patients with B-cell malignancies.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: October 09, 2018 - October 08, 2019
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Nathan H. Fowler, MD
Associate Professor of Medicine, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Nathan H. Fowler, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AbbVie Inc.; Celgene Corporation; F. Hoffmann-La Roche; Janssen Pharmaceuticals, Inc.; and TG Therapeutics, Inc.
Advisory Board for AbbVie Inc.; Celgene Corporation; F. Hoffmann-La Roche; Janssen Pharmaceuticals, Inc.; and TG Therapeutics, Inc.

Faculty

Matthew S. Davids, MD, MMSc
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Matthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca; Bristol-Myers Squibb; Genentech, Inc.; MEI Pharma Inc.; Pharmacyclics LLC; Surface Oncology; TG Therapeutics, Inc.; and Verastem, Inc.
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Celgene Corporation; Genentech, Inc.; Gilead; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pharmacyclics LLC; TG Therapeutics, Inc.; and Verastem, Inc.

Sonali M. Smith, MD
Elwood V. Jensen Professor in Medicine
Director, Lymphoma Program
The University of Chicago Medicine
Chicago, Illinois

Sonali M. Smith, MD, has no financial interests/relationships or affiliations in relation to this activity.
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Kite Pharma, Inc./Gilead; Pharmacyclics LLC; and Seattle Genetics, Inc.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6373-19-T.

Providership


This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc. and Pharmacyclics LLC, an AbbVie Company, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and TG Therapeutics, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.